[
  {
    "ts": "2026-01-20T06:09:59+00:00",
    "headline": "The Bull Case For Illumina (ILMN) Could Change Following Its Billion Cell Atlas Pharma Alliance",
    "summary": "Earlier in January 2026, Illumina announced the Billion Cell Atlas alliance with AstraZeneca, Merck, and Eli Lilly, alongside new AI‑enabled genomics and multiomics platforms that integrate CRISPR, single-cell sequencing, and cloud analytics to support drug discovery and precision medicine. This push into large-scale genomics datasets and multiomic software marks a shift toward data-driven services that could reshape how Illumina works with pharmaceutical partners across the drug development...",
    "url": "https://finance.yahoo.com/news/bull-case-illumina-ilmn-could-060959095.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "ea58a0a7-d615-3a9a-8028-2e5f7e204c7a",
      "content": {
        "id": "ea58a0a7-d615-3a9a-8028-2e5f7e204c7a",
        "contentType": "STORY",
        "title": "The Bull Case For Illumina (ILMN) Could Change Following Its Billion Cell Atlas Pharma Alliance",
        "description": "",
        "summary": "Earlier in January 2026, Illumina announced the Billion Cell Atlas alliance with AstraZeneca, Merck, and Eli Lilly, alongside new AI‑enabled genomics and multiomics platforms that integrate CRISPR, single-cell sequencing, and cloud analytics to support drug discovery and precision medicine. This push into large-scale genomics datasets and multiomic software marks a shift toward data-driven services that could reshape how Illumina works with pharmaceutical partners across the drug development...",
        "pubDate": "2026-01-20T06:09:59Z",
        "displayTime": "2026-01-20T06:09:59Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/b7362375b2727bfdfe4eb144bcc3fe6a",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dF3MhqhVQlxOrPlZ6576PQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b7362375b2727bfdfe4eb144bcc3fe6a.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iKEosOYcHiWIA3wbQNTRmQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/b7362375b2727bfdfe4eb144bcc3fe6a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bull-case-illumina-ilmn-could-060959095.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bull-case-illumina-ilmn-could-060959095.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ILMN"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]